Cannabis Rescheduling: Page 4

Glass House Brands Deconsolidates Dual-Use Business, Applies for Uplisting of Shares to NYSE

The U.S. cannabis company plans to list its subordinate voting shares on the New York Stock Exchange.

Anti-Rescheduling Parties Ask Court to Stay Schedule III Cannabis Order

A national drug screening association and a private pharmaceutical cannabinoid development company argue they’ll suffer irreparable harm.

Trulieve Approved to Uplist on New York Stock Exchange

The company announced its subordinate voting shares are expected to begin trading under the ticker ‘TRLV’ on June 10 on the NYSE.

5 ‘Aggrieved Persons’ Sue Trump, DOJ Over Cannabis Rescheduling Order

A substance abuse recovery clinic, two doctors, a victims’ advocacy organization and a pharmaceutical company claim the order was unlawful.

7 House Democrats Demand IRS, Treasury Provide 280E Cannabis Guidance

The U.S. representatives sent a letter urging ‘clear, timely guidance’ for state-licensed medical businesses following the DOJ’s rescheduling order.

ATACH Assembles Legal Team to Defend Schedule III, Defeat Prohibitionist Opponents

The American Trade Association for Cannabis and Hemp filed a formal notice to participate in the DEA hearing and retained Shane Pennington of Blank Rome.

Jushi Applies for DEA Registration of State-Licensed Medical Cannabis Operations

The multistate operator announced it is seeking expedited registration approval from the DEA under the federal Schedule III framework.

3 States Challenge Trump DOJ’s Schedule III Cannabis Rule

Nebraska, Indiana and Louisiana filed a petition for review in federal court, arguing that immediately rescheduling medical cannabis violates administrative procedures.

White House’s ‘New Legal Authority’ for Hemp THC Products Leads CBT’s Top Stories in May

The Trump administration’s drug control strategy indicated enforcement of intoxicating hemp products that have largely gone unregulated.

Cresco Labs Marks Historic Step Forward With Medical Cannabis Facility DEA Registrations

The registrations are for the company’s dispensary, cultivation and processing operations.

SAFE Banking Act Nowhere to Be Found in Wake of Schedule III Cannabis Order

The new federal posture toward loosening restrictions on cannabis does not appear to have increased congressional appetite for industry banking reform.

Cannabis Business Leans on Schedule III Listing, Asks US Tax Court to Recognize 280E Refunds for Prior Years

The IRS can’t dispute that medical cannabis falls outside the meaning of Schedule I or II ‘without contradicting the president, the acting attorney general and HHS,’ the company says.

Previous Page

Page 4 of 22

Next Page